Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Pomegranate-Prebiotic Supplementation for Sarcopenic Obesity

15 november 2026 bijgewerkt door: The Hong Kong Polytechnic University

The Efficacy of Pomegranate-Prebiotic Supplementation to Enhance Beneficial Phytochemicals in Older Adults With Sarcopenic Obesity

Sarcopenic obesity (SO) in older adults involves the co-occurrence of skeletal muscle decline and excessive body fat. This project investigates the gut-muscle axis, specifically how gut bacteria convert dietary polyphenols (such as ellagic acid found in pomegranates) into a muscle-protecting metabolite called Urolithin A (UA). This study is a randomized crossover pilot trial in 30 older adults with SO. It tests whether combining a pomegranate extract supplement with a prebiotic (Fructo-oligosaccharides, or FOS) increases the body's production of UA more effectively than pomegranate extract alone over a 7-day period.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Background and Rationale Sarcopenic obesity (SO) is a major public health challenge that significantly increases the risk of frailty, functional dependence, and metabolic comorbidities in aging populations. Current lifestyle and nutritional interventions often fail to address the underlying mitochondrial dysfunction and chronic low-grade inflammation central to the pathogenesis of SO. Recently, the gut-muscle axis has emerged as a therapeutic target. Urolithin A (UA) is a gut-derived microbial metabolite synthesized from dietary ellagitannins and ellagic acid (abundant in pomegranates) that activates mitophagy and improves mitochondrial health in skeletal muscle. However, UA synthesis is highly variable and depends on individual gut microbial composition, which is often compromised in older adults with obesity and sarcopenia (dysbiosis). Recent evidence suggests that prebiotics like Fructo-oligosaccharides (FOS) can promote the specific bacterial strains (Bifidobacterium and Enterococcus species) required for the two-step bioconversion of ellagic acid into UA.

This is a clinical pilot trial designed to test the feasibility and biological efficacy of a synergistic nutritional intervention. A total of 30 older adults diagnosed with SO will be enrolled in a randomized crossover trial. Each participant will undergo two 7-day intervention periods separated by a 14-day washout period.

Intervention A includes pomegranate extract alone (yielding 200 mg/day of ellagic acid). Intervention B includes pomegranate extract (yielding 200 mg/day of ellagic acid) combined with FOS prebiotic powder (5 g/day).

Because each participant serves as their own control, the crossover design eliminates the confounding effect of individual variability in baseline gut microbiome composition. The primary outcome is the within-participant difference in 24-hour urinary UA excretion (normalized to creatinine) between the combined intervention and the single-component intervention. Secondary outcomes include changes in fecal urolithin concentrations and shifts in gut microbiota composition assessed via 16S rRNA sequencing. Findings will inform the design of a fully powered randomized controlled trial testing this cost-effective synbiotic strategy for managing SO.

Studietype

Ingrijpend

Inschrijving (Geschat)

30

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Hong Kong, China
        • The Hong Kong Polytechnic University
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

65 jaar en ouder (Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • 65 years or older.
  • Confirmed diagnosis of Sarcopenic Obesity (SO) according to 2022 ESPEN-EASO consensus and AWGS criteria:
  • Obesity Component: BF% ≥25% (men) / ≥35% (women); OR BMI ≥23kg/m2; OR waist circumference >90cm (men) / >80cm (women).
  • Sarcopenia Component: Low relative skeletal muscle mass combined with low handgrip strength (<28 kg men / <18kg women) and/or low physical performance (5-time chair stand ≥12s or gait speed <1.0m/s).
  • Able and willing to provide informed consent.
  • Willing and able to comply with all study procedures, dietary supplementation, and sample collections (24-hour urine and fecal samples).

Exclusion Criteria:

  • Current regular intake of pomegranate, ellagitannin, or prebiotic supplements.
  • Known hypersensitivity or allergy to pomegranate or fructo-oligosaccharides (FOS).
  • History of renal diseases, renal replacement therapy, active cancer, severe cognitive impairment, or severe cardiac or hepatic dysfunction.
  • Exposure to systemic antibiotics within 3 months prior to enrollment.
  • Current participation in any other active interventional clinical trial.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Fundamentele wetenschap
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Pomegranate Extract Alone (Active Control)

Participants will complete a 7-day intervention period receiving dietary supplementation with pomegranate extract alone.

Two tablets daily of commercial pomegranate extract (Puritan's Pride), providing a total daily dose of 500 mg pomegranate fruit extract containing 200 mg ellagic acid (EA). Administered orally for 7 consecutive days.

Experimenteel: Pomegranate Extract + Fructo-oligosaccharides (FOS)

Participants will complete a 7-day intervention period receiving dietary supplementation with pomegranate extract in combination with FOS prebiotic powder.

Two tablets daily of commercial pomegranate extract (Puritan's Pride), providing a total daily dose of 500 mg pomegranate fruit extract containing 200 mg ellagic acid (EA). Administered orally for 7 consecutive days.

Two teaspoons (5 g/day) daily of Source Naturals FOS Powder. Provided as pre-measured daily sachets of bulk powder to be mixed with water, juice, or food and consumed orally for 7 consecutive days.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
24-Hour Urinary Urolithin A Excretion
Tijdsspanne: Day 7 of Period 1 and Day 7 of Period 2 (at the end of each 7-day intervention period).

Within-participant difference in 24-hour total urinary urolithin A excretion normalized to urinary creatinine between the Pomegranate Extract + FOS intervention period and the Pomegranate Extract Alone intervention period. Measured via UHPLC-MS/MS.

Day 7 of Period 1 and Day 7 of Period 2 (at the end of each 7-day intervention period).

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
24-Hour Total Urinary Urolithins Profile
Tijdsspanne: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.

Total excretion of urolithin metabolites and intermediates (including urolithin B and urolithin C) measured in 24-hour batch urine samples using UHPLC-MS/MS.

Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
Gut Microbiota Composition
Tijdsspanne: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.

Relative abundance and community structure of target gut bacteria (including Bifidobacterium species and urolithin-converting taxa) determined by 16S rRNA gene sequencing (V3-V4 hypervariable region) on an Illumina MiSeq platform.

Change from baseline (Day 0) to Day 7 within each 7-day intervention period.
Fecal Urolithin Concentrations
Tijdsspanne: Change from baseline (Day 0) to Day 7 within each 7-day intervention period.

Concentrations of urolithin A, urolithin B, and urolithin C in self-collected homogenized fecal samples, extracted and quantified via UHPLC-MS/MS.

Change from baseline (Day 0) to Day 7 within each 7-day intervention period.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 november 2026

Primaire voltooiing (Geschat)

1 december 2026

Studie voltooiing (Geschat)

1 december 2026

Studieregistratiedata

Eerst ingediend

15 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

15 november 2026

Eerst geplaatst (Werkelijk)

20 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

20 november 2026

Laatste update ingediend die voldeed aan QC-criteria

15 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • HSEARS20260821008

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .